Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of crizotinib alone or with temsirolimus in pediatric ALK-, ROS1-, or MET-positive malignancies
2023-504880-18-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of crizotinib and temsirolimus in anaplastic large cell lymphoma (ALCL), neuroblastoma, rhabdomyosarcoma (RMS) and 3 more (3 arms), sponsored by Erasmus MC. Primary endpoints: Dose-limiting toxicities and Overall response rate. Planned start Feb 2024; status: authorised.
02
Drugs
crizotinibtemsirolimus
03
Conditions
anaplastic large cell lymphoma (ALCL)neuroblastomarhabdomyosarcoma (RMS)inflammatory pseudotumor (IPT)Anaplastic Large Cell Lymphoma ALK-positive
Beyond the preview
Go deeper on 2023-504880-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504880-18-00.